Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study: could extra PRP injections around the knee boost pain relief?

NCT ID NCT07339137

Symptom relief Sponsor: Ankara City Hospital Bilkent Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two ways of giving platelet-rich plasma (PRP) injections for chronic knee osteoarthritis: one into the joint only, and another that also targets tissues around the knee. Researchers want to see if the combined approach better reduces pain, improves daily function, and affects ligament and cartilage thickness. The trial involves 42 adults aged 40-65 with moderate knee OA who haven't improved with standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 42 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Apr 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Age between 40 and 65 years. * Patients with significant medial knee pain who have not responded to conservative treatment for at least 3 months. * Patients diagnosed with knee osteoarthritis according to the American College of Rheumatology (ACR) criteria and with Kellgren-Lawrence grade 2 or 3 radiographic osteoarthritis. * Intact cognitive function. * Willingness to participate in the study and provide signed informed consent. * Visual Analog Scale (VAS) score of 4 or higher. Exclusion Criteria * History of previous knee trauma or surgery. * Physical therapy, intra-articular steroid, or hyaluronic acid injections in the knee within the last 3 months. * Active oncological diseases. * Local infection, sepsis, wounds, or scars in the injection area. * Systemic infections, hepatitis, or immunosuppression. * Bleeding diathesis or irregular International Normalized Ratio (INR) due to oral warfarin use. * Inflammatory arthropathies. * Uncontrolled hypertension, uncontrolled diabetes mellitus, decompensated heart failure, coronary artery disease, or asthma. * Suspected or confirmed pregnancy. * Use of corticosteroids or opioids. * Anemia. * Body mass index (BMI) greater than 35. * Allergy to citrate. * Use of nonsteroidal anti-inflammatory drugs (NSAIDs) within the last week that may affect platelet function analyzer-100 (PFA-100) activity. * Physical examination findings suggestive of patellar retinaculum, meniscus, or cruciate ligament injury. * General health impairment or lack of cooperation. * Refusal to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gonarthrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gonarthrosis Platelet rich plasma injection Ultrasonography

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ankara Bilkent City Hospital, Physical Therapy and Rehabilitation Hospital

    RECRUITING

    Ankara, Çankaya, 06800, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.